- Scope of the procurement
- Lot 1. CM/PHS/22/5561/01 Standard Half-life Recombinant Factor eight
- Lot 2. CM/PHS/22/5561/02 Enhanced Half-life Recombinant Factor eight
- Lot 3. CM/PHS/22/5561/03 Emicizumab
- Lot 4. CM/PHS/22/5561/04 eftrenonacog alfa (rFIX EHL)
- Lot 5. CM/PHS/22/5561/05 albutrepenonacog alfa (rFIX EHL)
- Lot 6. CM/PHS/22/5561/06 nonacog beta pegol (rFIX EHL)
- Lot 7. CM/PHS/22/5561/07 rFIX - Standard Half Life
- Lot 8. CM/PHS/22/5561/08 Recombinant Factor seven
- Lot 9. CM/PHS/22/5561/09 Porcine Factor eight - susoctocog alfa
- Lot 10. CM/PHS/22/5561/10 Factor eight Inhibitor Bypassing Fraction
- Lot 11. CM/PHS/22/5561/11 Factor IX - High Purity Factor IX
- Lot 12. CM/PHS/22/5561/12 Factor X
- Lot 13. CM/PHS/22/5561/13 Factor XIII - Plasma Derived
- Lot 14. CM/PHS/22/5561/14 Factor XIII - Recombinant
- Lot 15. CM/PHS/22/5561/15 Von willebrands factor / Factor eight
- Lot 16. CM/PHS/22/5561/16 Von willebrands factor - Plasma Derived
- Lot 17. CM/PHS/22/5561/17 Von willebrands factor - Recombinant
- Lot 18. CM/PHS/22/5561/18 Fibrinogen Concentrate
- Lot 19. CM/PHS/22/5561/19 Prothrombin Complex dried
- Lot 20. CM/PHS/22/5561/20 Protein C Concentrate
- Lot 21. CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups)
- Lot 22. CM/PHS/22/5561/22 Freeze Dried Plasma
- Lot 23. CM/PHS/22/5561/23 Caplacizumab
Section one: Contracting authority
one.1) Name and addresses
NHS England
1st Floor, Quarry House, Quarry Hill
Leeds
LS2 7UE
Contact
Katie Noonan
Country
United Kingdom
Region code
UKE - Yorkshire and the Humber
Internet address(es)
Main address
Buyer's address
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
https://health-family.force.com/s/Welcome
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
https://health-family.force.com/s/Welcome
Tenders or requests to participate must be submitted to the above-mentioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at
https://health-family.force.com/s/Welcome
one.4) Type of the contracting authority
Ministry or any other national or federal authority
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
NHS Framework - Blood Disorders including Haemophilia A and B - July 2024
Reference number
CM/PHS/22/5561
two.1.2) Main CPV code
- 33600000 - Pharmaceutical products
two.1.3) Type of contract
Supplies
two.1.4) Short description
Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024
Offer reference number: CM/PHS/22/5561
Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months.
Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England
two.1.5) Estimated total value
Value excluding VAT: £1,168,000,000
two.1.6) Information about lots
This contract is divided into lots: Yes
Tenders may be submitted for all lots
two.2) Description
two.2.1) Title
CM/PHS/22/5561/01 Standard Half-life Recombinant Factor VIII
Lot No
1
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
Standard Half-life Recombinant Factor VIII
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/02 Enhanced Half-life Recombinant Factor VIII
Lot No
2
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/02 Enhanced Half-life Recombinant Factor VIII
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/03 Emicizumab
Lot No
3
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/03 Emicizumab
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/04 eftrenonacog alfa (rFIX EHL)
Lot No
4
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/04 eftrenonacog alfa (rFIX EHL)
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/05 albutrepenonacog alfa (rFIX EHL)
Lot No
5
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/05 albutrepenonacog alfa (rFIX EHL)
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/06 nonacog beta pegol (rFIX EHL)
Lot No
6
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/06 nonacog beta pegol (rFIX EHL)
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/07 rFIX - Standard Half Life
Lot No
7
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/07 rFIX - Standard Half Life
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/08 Recombinant Factor VII
Lot No
8
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/08 Recombinant Factor VII
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/09 Porcine Factor VIII - susoctocog alfa
Lot No
9
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/09 Porcine Factor VIII - susoctocog alfa
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/10 Factor VIII Inhibitor Bypassing Fraction
Lot No
10
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/10 Factor VIII Inhibitor Bypassing Fraction
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/11 Factor IX - High Purity Factor IX
Lot No
11
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/11 Factor IX - High Purity Factor IX
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/12 Factor X
Lot No
12
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/12 Factor X
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/13 Factor XIII - Plasma Derived
Lot No
13
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/13 Factor XIII - Plasma Derived
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/14 Factor XIII - Recombinant
Lot No
14
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/14 Factor XIII - Recombinant
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/15 Von willebrands factor / Factor VIII
Lot No
15
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/15 Von willebrands factor / Factor VIII
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/16 Von willebrands factor - Plasma Derived
Lot No
16
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/16 Von willebrands factor - Plasma Derived
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/17 Von willebrands factor - Recombinant
Lot No
17
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/17 Von willebrands factor - Recombinant
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/18 Fibrinogen Concentrate
Lot No
18
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/18 Fibrinogen Concentrate
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/19 Prothrombin Complex dried
Lot No
19
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/19 Prothrombin Complex dried
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/20 Protein C Concentrate
Lot No
20
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/20 Protein C Concentrate
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups)
Lot No
21
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups)
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/22 Freeze Dried Plasma
Lot No
22
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/22 Freeze Dried Plasma
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CM/PHS/22/5561/23 Caplacizumab
Lot No
23
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
two.2.4) Description of the procurement
CM/PHS/22/5561/23 Caplacizumab
two.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
two.2.6) Estimated value
Value excluding VAT: £1
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start date
1 July 2024
End date
30 April 2027
This contract is subject to renewal
No
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: Yes
Description of options
There will be an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section three. Legal, economic, financial and technical information
three.1) Conditions for participation
three.1.2) Economic and financial standing
Selection criteria as stated in the procurement documents
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
Framework agreement with several operators
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
21 March 2024
Local time
1:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.6) Minimum time frame during which the tenderer must maintain the tender
Tender must be valid until: 19 June 2024
four.2.7) Conditions for opening of tenders
Date
21 March 2024
Local time
1:00pm
Place
Runcorn
Information about authorised persons and opening procedure
Medicines Procurement and Supply Chain Employee
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.2) Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
six.3) Additional information
RESPONDING TO THIS NOTICE;
Any supplier may be disqualified who does not respond to the following in the requisite manner:
1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at http://health.atamis.co.uk
Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:
1.1) If not already registered, Candidates should register on the eTendering portal at http://health.atamis.co.uk and click the link to register:
- agree to the user agreement
- populate company details
1.2) Once registered, candidates must register interest as follows:
- log to the portal
- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select
- review opportunity details and click "Register Interest"
- as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity)
1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis helpdesk at supporthealth@atamis.co.uk or by calling 0800 9956035 for technical assistance when completing responses.
2) General supplier information.
To manage and assess supplier information the Contracting Authority requests candidates provide their
company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:
2.1) If not already registered (the previous sid4gov password, login and details will still
be on the system), candidates must go to the following web page https://supplierregistration.cabinetoffice.gov.uk
and select "Register" at the top of the page.
Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B.
Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.
2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.
D&B data will be supplied automatically by D&B.
2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the
message function on the website.
OTHER CONTRACTING AUTHORITIES
The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.
six.4) Procedures for review
six.4.1) Review body
The High Court
The Strand
London
WC2A 2LL
Country
United Kingdom